Boston Scientific Watchman FLX (Left Atrial Appendage Closure Device)

Category: Cardiac Devices

In Stock

Specifications

Device Sizes:
- Available in multiple sizes ranging from 20 mm to 35 mm, ensuring precise fit across various anatomies.
Material:
- Constructed of a nitinol frame with a polyethylene terephthalate (PET) membrane covering the atrial-facing surface.
Design Features:
- Fully rounded frame for minimal trauma during implantation.
- 45-degree struts designed to accommodate a wider range of LAA anatomies.
- Stabilization anchors for secure placement and reduced migration risk.
Delivery System:
- Flexible delivery catheter with a distal articulation mechanism for controlled deployment.
- Enhanced maneuverability for accurate placement.
Imaging Requirements:
- Compatible with transesophageal echocardiography (TEE) and fluoroscopy for procedural guidance.
Anticoagulation Protocol:
- Requires short-term anticoagulation therapy post-implantation (typically 45 days), transitioning to aspirin-only or dual antiplatelet therapy based on patient evaluation.

Description
Request for a Quote

Description

Boston Scientific Watchman FLX (Left Atrial Appendage Closure Device)

- Flexibility for Complex Anatomies:
  - The Watchman FLX can adapt to various LAA shapes and sizes, making it suitable for a broader range of patients compared to previous models.
- Enhanced Safety:
  - The fully rounded design minimizes tissue injury and complications during implantation.
- Complete LAA Sealing:
  - The PET membrane ensures complete occlusion, reducing the risk of blood clots escaping the LAA.
- Improved Implantation Success Rates:
  - Simplified delivery and deployment systems contribute to higher procedural success.
- Long-Term Solution:
  - Offers a permanent alternative to long-term oral anticoagulants, which can pose bleeding risks.
- The Watchman FLX is an advanced Left Atrial Appendage Closure (LAAC) device designed to reduce stroke risk in patients with non-valvular atrial fibrillation (NVAF) who are unsuitable for long-term anticoagulation therapy. This innovative device permanently seals the left atrial appendage (LAA), a common site for blood clot formation in NVAF patients.

Request for a Quote